Kristin Ancell is an Oncology physician affiliated with Vanderbilt University Medical Center. OpenAlex indexes 32 publications with 4,003 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372320001
Telephone
615-322-3000Provider last certified this registry record 23 Mar 2022.
Clinical trials
- Satisfaction With Placement of Implantable Venous Access Devices in Patients With Solid Tumors
Sponsor: Vanderbilt University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
34.3%Cytochrome P450 17A1 Inhibitor16.1%Abiraterone Acetate100%Part D≥15 patientsKinase inhibitor7.2%Cabometyx30%Zelboraf25%Mekinist23%Tafinlar23%Part D<11 patients+ 3 more classes in this area
Nervous system
25.2%Opioid Agonist10.6%Oxycodone Hcl50%Morphine Sulfate Er18%Oxycodone-Acetaminophen17%Morphine Sulfate15%Part D<11 patientsSNRI3.9%Venlafaxine Hcl Er100%Part D<11 patients+ 5 more classes in this area
Metabolism & gastrointestinal
24.2%Corticosteroid17.4%Prednisone100%Part D≥32 patientsSerotonin-3 Receptor Antagonist3.5%Ondansetron Hcl100%Part D≥13 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A multi-center retrospective cohort study of patients with mCRPC who received lutetium Lu177 vipivotide tetraxetan.
Journal of Clinical Oncology
2024 - Temozolomide and nivolumab in patients with refractory metastatic melanoma (MM).
Journal of Clinical Oncology
2024 - Examination of irAE and treatment discontinuation irAE in patients with RCC with T effector phenotype.
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center
Brian Rini, MD
Vanderbilt University Medical Center
Jordan Berlin, MD
Vanderbilt University Medical Center
Julia Lewis, MD
Vanderbilt University Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”